Description of Invention:
Substituted 1,4,7,10-tetraaza cyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) has numerous desirable chelating qualities that make it useful for treating a number of cellular disorders. Presently available chelating agents lack specificity for their intended targets or do not adequately bind the chelated metal ion. These substituted DOTAs have a strong affinity for a number of metal ions. They can also be linked to biomolecules to form systems for delivering the chelated metal ion, which can be radiolabeled, to specific sites within a cell or organelle.
Inventors:
OA Gansow (NCI) K Kumar (NCI)
Patent Status:
DHHS Reference No. E-347-1986/0 --
U.S. Patent 5,428,154 issued on 27 Jul 1995
Portfolios: Cancer
Cancer -Therapeutics-Immunoconjugates-Conjugate Chemistry Cancer -Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220